24 October 2024 Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate.
Science writer David Levine provides the latest quarterly Special Report piece, looking at the drug prices in one therapy area that are getting on people's nerves so much that they might prompt drastic action from the White House to bring down the cost of medicines across the board. 29 September 2017
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has endorsed an update of the European Union label with immediate effect for Tresiba (insulin degludec) to include results from the DEVOTE trial on severe hypoglycemia. 29 September 2017
A new analysis from QuintilesIMS, which draws on the Medicines Use and Spending in the U.S. — A Review of 2016 and Outlook to 2021 report and the Outlook for Global Medicines Through 2021: Balancing Cost and Value, takes an in-depth look at the true drivers of US medicine spending. 29 September 2017
Puerto Rico, an unincorporated US territory in the Caribbean, has been a hub of pharmaceutical manufacturing for some time, but in the aftermath of hurricane Maria (and Irma), that has changed – at least for now, says Mark Schwartz, writing on the Hyman, Phelps & McNamara FDA Law Blog. 29 September 2017
Experts who carried out a study published in the British Journal of Clinical Pharmacology have found widespread instances of the adulteration of proprietary Chinese medicines (pCMs), in some cases causing ‘serious dangers’ to patients. 29 September 2017
Cardiovascular diseases (CVDs) are expected to be the fastest growing chronic illnesses between 2007 and 2017, growing at 9.5% annually, and accounting for the second largest number of non-communicable diseases (NCDs) patients after mental illnesses in India. 29 September 2017
As advancements in cancer therapies have been making headlines in recent years, cancer drug prices have significantly increased. The remaining question is, what are the economic impacts of the differentiations in cost of Food and Drug Administration-approved drugs and the purchasing power of individuals around the world? 29 September 2017
There was an emphasis on good times ahead in the communications put out by Merck KGaA as the German life sciences and pharma company welcomed analysts and investors to its 2017 Capital Markets Day on Thursday. 28 September 2017
Anglo-Swedish pharma major AstraZeneca may be the first multinational drugmaker operating in Russia that could sign a special investment contract with the Russian government, Denis Manturov, Russia’s Industry and Trade Minister has recently said. 28 September 2017
The US pharmaceutical industry has signaled its support for severe limitations on the length of opioid prescriptions, saying it would be happy if the current 30-day maximum was reduced to just seven days. 28 September 2017
Cancer is on the rise in India. With 1 million people diagnosed with it every year, some 700,000 of them die, making it one of the leading causes of death in the country, reports The Pharma Letter’s India correspondent. 28 September 2017
The fast-changing and pressurized environment in which they operate means pharma companies must now take a more aggressive approach to adopting new leadership structures, writes Waseem Noor, a consultant at the executive search firm Russell Reynolds Associates, in an Expert View piece. 28 September 2017
Foresee Pharmaceuticals has entered into an exclusive license and distribution agreement with Turkish biopharma company TRPharm for the commercialisation in Turkey and certain Middle East countries of Foresee's FP-001 program, LMIS (leuprolide mesylate injectable suspension) ready-to-use subcutaneous depot formulations. 28 September 2017
The European Commission (EC) approval of a combination involving Kisqali (ribociclib) for a large breast cancer indication last month led a senior executive from Swiss pharma giant Novartis to proclaim that it proved the company’s ‘recognized leadership in cancer research’. 27 September 2017
Danish diabetes care giant Novo Nordisk today announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for the treatment of diabetes in China, which it said has the world's highest number of adult diabetes patients. 27 September 2017
Yitzhak Peterburg, Teva’s last but one CEO, recently described the pharmaceutical industry as one of the last “traditional” industries, saying it was about to undergo “huge disruption.” 27 September 2017
The Final Budget Outcome papers released today reveal the enormous efforts of the members of Medicines Australia to keep expenditure low on the Pharmaceutical Benefits Scheme (PBS) while providing Australians with incredible access to breakthrough medicines. 26 September 2017
The share price of Ireland-incorporated drugmaker Allergan closed at $211.61 on Monday, up 3.4% for the day, after the company announced a $2 billion share buyback program and reiterated its pledge to pay down $3.75 billion of debt in 2018. 26 September 2017
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised. 25 October 2024
The US Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines and recommends Capvaxive (pneumococcal 21-valent conjugate vaccine) for pneumococcal vaccination in adults 50 years of age and older. 25 October 2024
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Sanofi reported 15.7% sales growth for the third quarter of the year, reaching 13.4 billion euros ($14.2 billion), with adjusted earnings per share (EPS) rising by 12.2% to 2.86 euros, surpassing many forecasts. 25 October 2024
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' Kisqali (ribociclib). 24 October 2024
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 (20-valent pneumococcal conjugate vaccine) for all adults aged 50 and older. 24 October 2024
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.